Zhejiang Wecome Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Zhejiang Wecome Pharmaceutical's earnings have been declining at an average annual rate of -37.2%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been declining at an average rate of 9.5% per year.
Key information
-37.2%
Earnings growth rate
-42.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | -9.5% |
| Return on equity | -0.7% |
| Net Margin | -2.1% |
| Next Earnings Update | 30 Aug 2024 |
Revenue & Expenses Breakdown
How Zhejiang Wecome Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 524 | -11 | 252 | 37 |
| 31 Dec 23 | 520 | -8 | 238 | 43 |
| 30 Sep 23 | 489 | 20 | 209 | 31 |
| 30 Jun 23 | 552 | 52 | 217 | 38 |
| 31 Mar 23 | 544 | 53 | 228 | 40 |
| 01 Jan 23 | 532 | 49 | 238 | 39 |
| 30 Sep 22 | 606 | 98 | 220 | 49 |
| 30 Jun 22 | 597 | 90 | 248 | 46 |
| 31 Mar 22 | 684 | 99 | 305 | 41 |
| 01 Jan 22 | 633 | 96 | 303 | 37 |
| 30 Sep 21 | 652 | 139 | 321 | 22 |
| 30 Jun 21 | 648 | 142 | 315 | 21 |
| 31 Mar 21 | 632 | 140 | 303 | 19 |
| 31 Dec 20 | 623 | 136 | 306 | 19 |
| 30 Sep 20 | 660 | 132 | 323 | 19 |
| 30 Jun 20 | 648 | 127 | 321 | 19 |
| 31 Mar 20 | 614 | 113 | 306 | 22 |
| 31 Dec 19 | 642 | 126 | 320 | 21 |
| 31 Dec 18 | 578 | 88 | 314 | 16 |
| 31 Dec 17 | 407 | 95 | 164 | 16 |
| 31 Dec 16 | 282 | 81 | 75 | 14 |
| 31 Dec 15 | 208 | 50 | 62 | 0 |
| 31 Dec 14 | 153 | 21 | 47 | 0 |
| 31 Dec 13 | 135 | 20 | 38 | 0 |
Quality Earnings: 300878 is currently unprofitable.
Growing Profit Margin: 300878 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300878 is unprofitable, and losses have increased over the past 5 years at a rate of 37.2% per year.
Accelerating Growth: Unable to compare 300878's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 300878 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.8%).
Return on Equity
High ROE: 300878 has a negative Return on Equity (-0.71%), as it is currently unprofitable.